Welcome to our dedicated page for Exelixis news (Ticker: EXEL), a resource for investors and traders seeking the latest updates and insights on Exelixis stock.
Exelixis, Inc. (EXEL) is an oncology-focused biopharmaceutical company whose news flow centers on cancer therapeutics, clinical trial milestones and financial performance. The company’s updates frequently highlight the commercial progress of its cabozantinib franchise, marketed in the U.S. as CABOMETYX and COMETRIQ, as well as pivotal data and regulatory steps for its investigational kinase inhibitor zanzalintinib.
Investors following EXEL news can expect regular announcements on quarterly and annual financial results, including net product revenues for the cabozantinib franchise, research and development spending and stock repurchase authorizations. Exelixis also issues news releases around guidance for upcoming fiscal years and commentary from management on commercial and pipeline priorities.
A significant portion of Exelixis’ news coverage focuses on clinical and regulatory developments. Recent communications describe detailed results from the STELLAR-303 phase 3 trial of zanzalintinib plus atezolizumab in metastatic colorectal cancer, the planned and ongoing STELLAR-304 and STELLAR-311 pivotal trials in renal cell carcinoma and neuroendocrine tumors, and collaborations such as STELLAR-316 with Natera’s Signatera assay for molecular residual disease–guided therapy. Additional news addresses subgroup analyses from the CABINET trial of CABOMETYX in advanced neuroendocrine tumors and regulatory approvals for cabozantinib-based therapies in various indications.
Corporate and investor-relations events are another recurring theme in EXEL news. The company announces participation in major healthcare and investor conferences, R&D-focused webcasts and leadership changes disclosed via Form 8-K. For readers tracking oncology pipelines, solid tumor trial data and the commercial trajectory of CABOMETYX and zanzalintinib, the Exelixis news stream provides ongoing insight into the company’s scientific, clinical and financial developments.
Exelixis (Nasdaq: EXEL) announced that the U.S. FDA accepted its New Drug Application for zanzalintinib combined with atezolizumab for previously treated metastatic colorectal cancer.
The FDA set a standard review PDUFA target action date of December 3, 2026. The NDA is supported by phase 3 STELLAR-303, which showed a statistically significant overall survival benefit versus regorafenib in the intention-to-treat population; some endpoint data remain immature with a planned final analysis expected in mid-2026.
Exelixis (Nasdaq: EXEL) will release fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026 after market close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT to discuss results and provide a business update.
Access is available via the company website Event Calendar under Investors & News; registrants for the call receive a dial-in number and unique PIN. A webcast replay will be archived on the website for one year.
Exelixis (Nasdaq: EXEL) reported preliminary unaudited fiscal 2025 results and issued 2026 guidance. Key figures include cabozantinib U.S. net product revenues of ~$2.123 billion for FY2025 and FY2026 net product revenue guidance of $2.325–$2.425 billion (assumes a 3.0% U.S. WAC increase). Fiscal 2025 R&D was ~$825 million and FY2026 R&D guidance is $875–$925 million. Ending cash and marketable securities were ~$1.65 billion. The company highlighted multiple mid-2026 clinical readouts for zanzalintinib and ongoing pivotal trials, plus an additional $750 million share repurchase authorization.
Summary not available.
Exelixis (NASDAQ: EXEL) announced that Michael M. Morrissey, Ph.D., president and CEO, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET.
The presentation will be webcast and accessible via www.exelixis.com under the Event Calendar on the Investors & News page. A replay will be available at the same location for at least 30 days.
Exelixis (NASDAQ: EXEL) will webcast a virtual 2025 R&D Day titled Building Next-generation Oncology Franchises on Wednesday, December 10, 2025 from 1:00 p.m. to 3:30 p.m. EST. Featured speakers will review Exelixis' R&D progress and outline the company strategy to advance future oncology franchises, with a focus on raising standards of care and generating long-term shareholder value.
The live webcast and a recording will be available at EXELRDDay.com and on the company Event Calendar at exelixis.com under Investors & News; content will remain accessible for one year. Registration uses code EXELR&D; participants are encouraged to register in advance for timely access.
Exelixis (NASDAQ: EXEL) announced that management will participate in fireside chats at two investor conferences in November with live webcasts and replays.
Schedule: Guggenheim Healthcare Innovation on Monday, November 10, 2025 at 10:30 a.m. ET / 7:30 a.m. PT in Boston; Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 8:40 a.m. ET / 5:40 a.m. PT in New York City. Webcasts and replays will be available via the company's Event Calendar at www.exelixis.com for at least 30 days.
Exelixis (Nasdaq: EXEL) reported Q3 2025 total revenues of $597.8M and cabozantinib U.S. net product revenues of $542.9M. GAAP diluted EPS was $0.69 and non-GAAP diluted EPS was $0.78. The company announced an additional $750M stock repurchase program to be completed by the end of 2026 and updated 2025 guidance with total revenues of $2.30B–$2.35B and net product revenues of $2.10B–$2.15B. Exelixis plans to submit a U.S. NDA for zanzalintinib by year-end after positive STELLAR-303 OS results; CABOMETYX approvals for NETs were expanded in 2025 in the U.S., EU, Brazil and Australia. Restructuring charges and guidance changes were also disclosed.
Exelixis (Nasdaq: EXEL) will release third quarter 2025 financial results on Tuesday, November 4, 2025 after markets close. Management will host a conference call and live webcast the same day at 5:00 p.m. ET / 2:00 p.m. PT to discuss results and provide a business update.
Investors can access the event via the company website. Telephone access requires registration, which provides a dial-in number and unique PIN. A webcast replay will be archived on the company website for one year.
Exelixis (NASDAQ: EXEL) reported detailed Phase 3 STELLAR-303 results for zanzalintinib + atezolizumab in previously treated non‑MSI‑high metastatic colorectal cancer presented at ESMO 2025 and published in The Lancet. In the ITT population the combination reduced risk of death by 20% (stratified HR 0.80; 95% CI 0.69–0.93; P=0.0045) with median OS 10.9 months versus 9.4 months for regorafenib at 18.0‑month follow‑up. PFS trended favorably (HR 0.68; median 3.7 vs 2.0 months). Safety showed higher grade 3/4 AEs (59% vs 37%) and modestly higher discontinuations. Exelixis plans a U.S. NDA submission in 2025.
FAQ
What is the current stock price of Exelixis (EXEL)?
What is the market cap of Exelixis (EXEL)?
